Emcure Pharma announces deal with Sanofi India to distribute oral anti-diabetic products in India

Emcure Pharma partners with Sanofi India

Emcure Pharma on July 16 announced that it has entered into an exclusive distribution and promotion agreement with Sanofi India for the latter's oral anti-diabetic (OAD) products in India.

As part of the agreement, Emcure will exclusively distribute and promote Sanofi's OAD range of products, which includes popular brands like Amaryl and Cetapin, the company said in its press release.

"While SIL will continue to own and manufacture these brands across Sanofi's plants in India and internationally, Emcure will leverage its strengths to engage healthcare professionals and expand reach of these therapeutic solutions for patients who need them across all of India," the firm added.

Notably, there will be no transition of executives under this partnership, the firm added.

Also read: No health warning on food products such as samosas, jalebi, and laddoo, says Health Ministry

Speaking about the partnership, Emcure Pharma CEO and MD Satish Mehta said, "At Emcure, we are committed to improving patient access to high-quality therapies. With our strong distribution network in India, Sanofi's trusted oral anti-diabetic medicines will be available to more patients who need them. This collaboration complements our existing diabetes portfolio, creating a comprehensive offering for the millions living with diabetes and supporting better diabetes care across the country."

Over 100 million Indians are living with type 2 diabetes and its complexities in India, said Eric Mansion, General Manager Pharma Southeast Asia and India & MCO Lead at Sanofi. "Of these, >60% people are living with uncontrolled blood sugar levels and have a higher risk of developing complications, over a long period of time," he added.

"Sanofi's commitment to improving their lives and helping them manage their diabetes better remains unwavering. With Emcure’s wide and deeply penetrated presence across India, we’re confident of tapping into the full growth potential of our best-in-class & industry-leading OADs Amaryl and Cetapin. This partnership will truly benefit both – the patients who need them and the HCPs who trust and prescribe them," Mansion further said.

Also read: Jio BlackRock Mutual Fund gets SEBI nod to launch 4 passive funds

The announcement was made in the post market hours of July 16. The shares of the two companies will remain in focus tomorrow, when the market reopens.